Aytu BioPharma, Inc.

Total Valuation

Aytu BioPharma, Inc. carries a market capitalization of 22.17M, placing it among publicly traded companies globally. Its enterprise value stands at 13.80M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Aytu BioPharma, Inc. currently has 10.73M shares outstanding.

Valuation Ratios

The price-to-sales ratio is 0.46, and the price-to-book ratio stands at 0.65.

Enterprise Valuation

On an enterprise value basis, Aytu BioPharma, Inc. trades at an EV/EBITDA multiple of 7.13 and an EV/FCF ratio of 2.65. The EV/Sales ratio of 0.24 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 11.18 provides insight into valuation relative to core operating earnings.

Financial Position

Aytu BioPharma, Inc. maintains a current ratio of 1.13, meaning it holds 1.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 48.28, indicating elevated leverage, while an interest coverage ratio of -2.31 demonstrates limited ability to service its debt obligations.

Financial Efficiency

Taxes

Stock Price Statistics

Aytu BioPharma, Inc.'s stock has declined approximately -13.55932% over the past 52 weeks. The 50-day moving average sits at 2.17, while the 200-day moving average is 2.35.

Income Statement

Over the trailing twelve months, Aytu BioPharma, Inc. generated 57.57M in revenue and converted that into -14.25M in net income, yielding earnings per share of -0.96. EBITDA reached -4.38M, while operating income came in at -8.31M.

Balance Sheet

Aytu BioPharma, Inc. holds 26.31M in cash and equivalents against 17.03M in total debt, resulting in a net debt position of -9.28M. Total book value stands at 35.27M, with working capital of 7.10M providing operational flexibility.

Cash Flow

Aytu BioPharma, Inc. produced 3.28M in operating cash flow over the past twelve months. After subtracting -29,000.00 in capital expenditures, free cash flow totaled 3.25M - equivalent to 0.26 per share.

Margins

Aytu BioPharma, Inc. operates with a gross margin of 63.95, reflecting its pricing power and cost economics. The operating margin of -14.44 and net profit margin of -24.76 provide insight into operational efficiency.

Dividends & Yields

Stock Splits

Aytu BioPharma, Inc.'s most recent stock split took place on January 6, 2023 with a 20:1 split ratio.

Scores

Aytu BioPharma, Inc. posts an Altman Z-Score of -6.85, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.